Found safe & effective in a wide range of patients

RESPeRATE was found safe and effective in populations ranging from healthy normotensive [27] to refractory hypertensives [5].

The studies performed in the US, Europe, Middle East, and the Far East also found it was effective in patients with comorbidities as diabetes [9, 11, 18], chronic kidney failure [19], pulmonary arterial hypertension [21], CHF [23, 32-39], COPD [40] and more.

Weighted average from the studies was 10/5 mmHg sustained office BP reduction in adults both with controlled and uncontrolled BP.

BP reductions were independent of gender and medication status.

Safe & effective for the most severe patients

Studies [2-8,10-11] showed that patients over 65 saw greater BP reductions averaging 16/7 mmHg.

They also demonstrated that patients with stage 2 hypertension (systolic BP>160 mmHg) saw larger reductions averaging 17/7 mmHg.

Greater reductions with greater use

The randomized controlled study [6] that won RESPeRATE it’s FDA-clearance for use without a prescription (OTC) demonstrated that slow breathing was the “active component” and a “dose-response.”

Using RESPeRATE for only 45 minutes a week of slow breathing delivers significant blood pressure reductions.

Using RESPeRATE more yields an even larger reduction.

Proven to dilate blood vessels

Eight studies demonstrated the physiological mechanism of action behind RESPeRATE effects. See the scheme in the medical textbook Hypertension Primer [24].

The studies demonstrated that RESPeRATE delivers an acute reduction of the sympathetic neural activity [22, 23, 25-27], resulting among other things in a sustained decrease in peripheral resistance and arterial stiffness [28-30].

Benefits beyond blood pressure

Beyond the 19 clinical studies in hypertension, independent researchers around the world have published more than 30 additional clinical studies demonstrating the various cardiopulmonary and neurological benefits of RESPeRATE.

Enclosed is a breakdown of some of published clinical studies demonstrating that RESPeRATE might be beneficial in the following conditions:

• Lowering neural sympathetic activity (acutely): 5 studies [22, 23, 25-27]
• Sustained decrease in peripheral resistance and arterial stiffness: 3 studies [28-31]
• Benefiting Heart-failure patients: 8 studies [23, 32-38]
• Benefiting COPD patients. 3 studies [39-41]
• Benefiting PTSD and anxiety patients: 7 studies [41, 42, 44-48]
• Reducing chronic stress [43]
• Improving sleep quality [21, 52, 53]

Please note that RESPeRATE has been cleared for marketing only for lowering blood pressure and stress.